risedronate / Generic mfg. - LARVOL DELTA

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Harbin Medical University

New P2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

DoE-based Development of Transdermal Risedronate-laden Cubosomes: In Vitro Characterization, Drug Deposition, and In Vivo Permeation in Rats. (PubMed, AAPS PharmSciTech) - "In vivo pharmacokinetic evaluation demonstrated a 1.39-fold enhancement in bioavailability relative to plain risedronate and a 3-fold improvement compared to marketed oral tablets. Collectively, these findings establish risedronate-laden cubosomal gel as a promising patient-friendly transdermal delivery system for long-term management of osteoporosis."

Journal • Preclinical • Osteoporosis • Rheumatology

Adequacy of pharmacological prescriptions in women with postmenopausal osteoporosis attended in a Primary Care center (PubMed, Aten Primaria) - "Adequacy of pharmacological prescriptions for osteoporosis was moderate, being higher for the therapeutic indication than for the first-line drug."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Expected change: a new concept for monitoring patients on oral bisphosphonates. (PubMed, J Bone Miner Res) - "We studied 108 postmenopausal women (age<85 years) who were randomised to the licensed dose of alendronate, ibandronate or risedronate treatment for two years, along with calcium and vitamin D supplementation. We required the expected change to exceed the least significant change, and this was not observed for LS- and THBMD, but it was observed for CTX and PINP (expected changes of 0.233 ng/mL and 12.1 ng/mL, respectively). Thus, the bone turnover markers CTX and PINP showed the best performance as response markers for monitoring oral bisphosphonate treatment, and the new approach is based on a biological rather than a statistical endpoint when using the expected change approach."

Journal • Osteoporosis • Rheumatology

Umbrella Clinical Study of Precision Therapy for Bone and Soft Tissue Sarcomas Based on Different Targets (ChiCTR) - P=N/A | N=50 | Not yet recruiting | Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital

New trial • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • BCL2 • HER-2 • NECTIN4

A novel approach for discriminating lipophilic bisphosphonate-based pharmaceuticals using a potentiometric array. (PubMed, Anal Methods) - "The lipophilicity of bisphosphonates including ibandronate, clodronate, risedronate, and alendronate was analyzed in both standard and commercial samples. The influence of membrane composition (presence or absence of an anion-exchanger) and PANI deposition conditions (monomer form and/or salt content) on membrane surface properties (lipophilicity and signal stability) was investigated and confirmed using surface-wetting characterization, SEM-EDS mapping and potentiometry. Principal component analysis (PCA) enabled discrimination among the bisphosphonates based on their lipophilicity and revealed distinct contributions of individual ISMs in both standard and commercial samples."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Osteoporosis • Rare Diseases • Rheumatology

Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis. (PubMed, Front Oncol) - "Seventeen RCTs involving 6,932 postmenopausal patients were included, comparing six interventions: denosumab, alendronate, zoledronic acid, ibandronate, risedronate, and eldecalcitol plus risedronate. Further head-to-head trials are warranted to validate optimal treatment sequences. PROSPERO (CRD420251008444)."

HEOR • Journal • Retrospective data • Review • Breast Cancer • Oncology • Solid Tumor

Bisphosphonates use is associated with increased coronary artery calcification in the general population: The Rotterdam study. (PubMed, Atheroscler Plus) - "Long-term bisphosphonate use is associated with increased arterial calcification, most notably with increased CAC, with a dose-response relationship further strengthening this observation. Large-scale observational studies are encouraged to use advanced causal inference methods to evaluate this long-term association and provide additional evidence to strengthen the causal interpretation."

Journal • Atherosclerosis • Cardiovascular

Enhancement of oral bioavailability of risedronate through xyloglucan rafts. (PubMed, J Pharm Pharm Sci) - "When compared to the RDN suspension, the pharmacokinetics revealed better RDN values from the XLG raft. The RDN from the recently developed XR5 has a better bioavailability than the Actonel® tablet."

Journal

Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database. (PubMed, Front Endocrinol (Lausanne)) - "Combination therapies synergistically amplified risk, with sequential administration of zoledronic acid yielding the highest ROR at 726.43 (95% CI: 642.83-820.90) and an accelerated time to onset (median 378 days vs. 462 days for monotherapy)...Weibull analysis demonstrated wear-out failure (β>1) in most subgroups, indicating cumulative toxicity; however, random failure patterns (β≈1) were observed with: 60 mg dosing and either sequential therapies (alendronate/ibandronate/risedronate) or combination therapy with methotrexate. This study demonstrates that the risk of denosumab-related ONJ is multifactorial, driven by high-dose regimens (120 mg Q4w), specific polypharmacy (particularly concomitant bisphosphonates and glucocorticoids) and male sex. These findings underscore the need for prospective validation and mechanistic investigation into the underlying drug interactions."

Adverse events • Journal

Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs. (PubMed, Viruses) - "Oxytocin and risedronate sodium were shown to influence the activities of Mpro and PLpro, thereby preventing the virus from replication, which may alleviate SARS-CoV-2 infection. Thus, oxytocin, risedronate sodium, and cephalosporins may expand the drug library for treating coronavirus infection."

Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

Bisphosphonates and Periodontal Health: A Systematic Review in Postmenopausal Women. (PubMed, J Midlife Health) - "BPs studied included zoledronic acid, alendronate, and risedronate, administered via IV, oral, or local delivery...Alendronate outperformed atorvastatin and placebo in several studies for periodontal outcomes. Bisphosphonate therapy, in various forms, provides significant benefits in managing periodontitis among postmenopausal women, with improvements noted in clinical, radiographic, and biochemical parameters. Further high-quality research is necessary to optimize treatment protocols and ensure long-term safety."

Journal • Review • Dental Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Periodontitis • Rheumatology

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis. (PubMed, Front Pharmacol) - "At 6 months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, raloxifene, teriparatide + alendronate, and zoledronic acid were beneficial in increasing BMD, with denosumab ranking highest (based on surface under the cumulative ranking curve (SUCRA) values). At 12 months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, risedronate, and zoledronic acid showed benefits, with alendronate + alfacalcidol ranking highest (SUCRA = 0.97)...Analysis of BMD at 5-10 years, involving four studies on alendronate, pamidronate, and placebo, indicated that alendronate achieved the highest SUCRA value (0.87)...Denosumab was the most efficient agent for increasing BMD at 6 months post-THA, while alendronate combined with alfacalcidol or feriparatide was most efficient at 12 months and 24 months. More high-quality direct comparisons and long-term follow-up studies are needed to determine the optimal drug and dosage for THA..."

Journal • Retrospective data • Orthopedics • Osteoporosis • Rheumatology

Custo-Efetividade da Teriparatida em Homens com Osteoporose Grave no Brasil. (PubMed, Value Health Reg Issues) - "In the analyzed scenarios, the use of bisphosphonates produces resource savings in relation to teriparatide in the treatment of men. Teriparatide was not cost-effective in any situation."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Moreover, immunocytochemistry suggested that RIS inhibits protein prenylation-dependent expression of p-ERK 1/2, RhoA, and ROCK1 in NRK-52E cells. Indeed, the study findings indicated that RIS treatment modulated renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling axis, holding the clinical promise in CKD management."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease • CTGF • IL6 • RHOA • TGFB1 • TNFA

Transdermal delivery of risedronate via spanlastics for osteoporosis: formulation optimization, skin deposition, and pharmacokinetic assessment. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Risedronate-loaded spanlastics represent a promising transdermal delivery system that overcomes oral limitations by improving bioavailability and skin permeation. Still, further investigation of risedronate-loaded spanlastics gel in in vivo pharmacodynamics studies is necessary to confirm its potential in the long-term treatment of osteoporosis."

Journal • PK/PD data • Osteoporosis • Rheumatology

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. (PubMed, Endocr Connect) - "Among 6,965 ocular AE reports for five BPs (alendronate, zoledronate, pamidronate, risedronate, and ibandronate), 136 positive signals were identified, predominantly unlisted in drug labels. This study identifies high-risk and novel ocular AEs related to BPs. These findings warrant further validation in future studies."

Adverse events • Journal • Age-related Macular Degeneration • Cataract • Glaucoma • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Khyber Medical University Peshawar

New trial • Osteoporosis • Rheumatology

γ9δ2 T cells detect mevalonate diphosphate via BTN3A3. (PubMed, Cell Mol Life Sci) - "LC-MS showed that 6-FM-treated CHO-K1 cells accumulated substantial MPP while risedronate, an inhibitor of farnesyl diphosphate synthase, primarily increased DMAPP/IPP...Both BTN2A1 + BTN3A3-transfected CHO-K1 cells and BTN3A1 knockout K562 cells could detect 6-FM, despite their absence of BTN3A1. Our findings provide evidence that MPP functions as a natural ligand of BTN3A3 and establish a foundation for elucidating biological functions of BTN3A3 complementary to the established BTN3A1 pathway."

Journal • Oncology • Targeted Protein Degradation • BTN2A1 • BTN3A1

Semaglutide-Induced FATAL Acute Necrotizing Pancreatitis Complicated by ARDS and Septic Shock (ACG 2025) - "Medications included lisinopril, risedronate, rosuvastatin, alprazolam, and semaglutide, started 1–2 weeks earlier, with the last dose 2 days before presentation...Hemodialysis was initiated for acute renal failure, and ventricular tachycardia was managed with amiodarone and cardioversion...After family discussions, a DNR/DNI order was established, and she succumbed to septic shock and ARDS, likely triggered by semaglutide-induced pancreatitis. This case highlights the rare but severe risk of semaglutide-associated necrotizing pancreatitis, particularly in patients with pre-existing pancreatic pathology. Clinicians should exercise caution when prescribing GLP-1 receptor agonists to such patients and monitor closely for early pancreatitis symptoms to prevent catastrophic outcomes.Figure: Acute pancreatitis with proximal pancreatic hypoenhancement, indicating necrosis, without peripancreatic fluid collections.Figure: Coronal view showing Acute pancreatitis with proximal..."

Acute Kidney Injury • Acute Respiratory Distress Syndrome • Anesthesia • Cardiovascular • Diabetes • Diabetic Nephropathy • Dyslipidemia • Endocrine Disorders • Hypertension • Metabolic Disorders • Mood Disorders • Osteoporosis • Pancreatic Cancer • Pancreatitis • Psychiatry • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Septic Shock • Ventricular Tachycardia

Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States (ACR Convergence 2025) - "Anabolic therapy (AT), the RANKL inhibitor denosumab (Dmab), and intravenous zoledronic acid (ZOL) are recommended as initial therapy for patients at very high risk (VHR) for fracture...OP medications included oral bisphosphonates (BPs; alendronate, risedronate, ibandronate), Dmab, ZOL, and AT (romosozumab, parathyroid hormone analogues [teriparatide, abaloparatide])... More than 1/3 of untreated PMO women are at VHR for fracture and eligible for ATs, Dmab, or ZOL in accordance with treatment guidelines. Among treated VHR PMO women, over half were treated with oral BP in contradiction with current treatment guidelines. Only a small percentage were treated with ATs, which clinical studies have shown are the most effective initial therapy for PMO women at VHR for fracture."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rare Diseases • Rheumatology

Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications (ACR Convergence 2025) - "Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular events (MACE), while denosumab (DMB) and teriparatide (TPT) have shown associations with select cardiovascular events in some reports [1–3]. Evidence for alendronate (ALN) and zoledronic acid (ZOL) is mixed, with some studies linking ZOL to atrial fibrillation (A-fib) [4–5]. Limited data exist for risedronate (RIS) and abaloparatide (ABA), with no consistent evidence of increased cardiovascular risk [1,4]... We found that among the drugs considered, only ROM was associated with increased ROR for all MACE outcomes. In contrast, DMB and ABA demonstrated relatively low cardiovascular risk signals across most outcomes. ZOL showed notable positive associations with both stroke and A-fib, while ALN was linked to increased reporting of A-fib and CF.Our findings suggest that a patient's individual risk for MACE should be considered when choosing osteoporosis drugs."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Musculoskeletal Diseases • Myocardial Infarction • Orthopedics • Osteoporosis • Rheumatology

RISEDRONATE AS AN UNDERRECOGNIZED CAUSE OF INCREASED OSMOLAR GAP (CHEST 2025) - "Both the patient and his partner denied ingestion of aspirin, acetaminophen, rubbing alcohol, or antifreeze. This case underscores acetone's potential role in increasing the osmolar gap, particularly in malnourished patients with alcoholic ketoacidosis. Recognizing this association is crucial for timely diagnosis and effective ICU management."

Addiction (Opioid and Alcohol) • Ataxia • CNS Disorders • Depression • Metabolic Disorders • Movement Disorders • Otorhinolaryngology • Psychiatry • Sleep Disorder

Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion. (PubMed, World Neurosurg) - "Osteoporosis is linked to higher reoperation and medical complications following lumbar fusion. Although osteoporosis medications did not significantly alter reoperation risk, their potential role in perioperative optimization requires further investigation."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Nephrology • Orthopedics • Osteoporosis • Pneumonia • Respiratory Diseases • Rheumatology • Thrombosis

Engineering a BMP2-risedronate complex with sustained release for osteoporosis therapy. (PubMed, Arch Pharm Res) - "In vivo studies confirmed that fabricated BMP2-risedronate complex loaded in hydrogels promotes sustained BMP2 release and, in combination with risedronate, enhances osteogenic efficacy. These findings suggest that the BMP2-risedronate ionic complex is a promising candidate for localized BMP2 delivery in osteogenesis therapy."

Journal • Osteoporosis • Rheumatology • BMP2